A New Era in Prostate Cancer Treatment? Understanding DNA Repair Deficiencies and the Therapeutic Rationale for PARP Inhibition

Video Module - In this on-demand Webcast of a CCO symposium at ASCO GU 2018, Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD; Emmanuel S. Antonarakis, MBBCh, and Heather H. Cheng, MD, PhD, review and discuss the latest data on DNA repair defects, genetic testing, and the use of PARP inhibitors in men with prostate cancer.
Source: Clinical Care Options Prostate Cancer - Category: Cancer & Oncology Source Type: research